肿瘤微环境在弥漫大B细胞淋巴瘤中的研究现状
Research Status of Tumor Microenvironment in Diffuse Large B-Cell Lymphoma
摘要: 弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma, DLBCL)是最常见的包含大细胞或转化B细胞的侵袭性异质性肿瘤,约占全部非霍奇金淋巴瘤的25%~50%。是一组高度分子异质性的疾病,细胞遗传学、基因表达谱和全基因组测序能够检测到多种复杂的染色体易位和遗传学异常。肿瘤微环境(tumor microenvironment, TME)是指肿瘤或癌干细胞存在的细胞周围环境,包括肿瘤周围的免疫细胞、血管、细胞外基质、成纤维细胞、肥大细胞和各类信号分子等。近年来,人们逐渐认识到肿瘤的增殖、浸润和转移既取决于肿瘤细胞自身,又依赖于TME中各种细胞以及信号分子的调控。随着人们对免疫治疗的研究进一步深入,TME作为肿瘤整体的重要组成部分,现在已经被认为对肿瘤的发生、发展以及治疗有着重要的调节作用。本文对TME在弥漫大B细胞淋巴瘤中的预后及治疗研究现状进行综述。
Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common invasive and heterogeneous tumor containing large or transformed B cells, accounting for 25%~50% of all non-Hodgkin lymphomas. As a group of diseases with high molecular heterogeneity, cytogenetics, gene expression profiles, and whole genome sequencing enable the detection of multiple complex chromosomal transloca-tions and genetic abnormalities. Tumor microenvironment (TME) refers to the tumor or cancer stem cells of the surrounding environment, including immune cells, blood vessels around the tu-mor, extracellular matrix, fibroblasts, mast cells, and all kinds of signaling molecules, etc. In recent years, people have gradually realized that the proliferation, invasion and metastasis of tumors de-pend not only on the tumor cells themselves, but also on the regulation of various cells and signal-ing molecules in TME. With the further development of immunotherapy research, TME, as an im-portant part of the tumor as a whole, has been considered to have an important regulatory role in the occurrence, development and treatment of tumors. This article reviews the prognosis and treatment of TME in diffuse large B-cell lymphoma.
文章引用:刘维佳, 高大. 肿瘤微环境在弥漫大B细胞淋巴瘤中的研究现状[J]. 临床医学进展, 2024, 14(2): 2507-2512. https://doi.org/10.12677/ACM.2024.142352

参考文献

[1] 中国抗癌协会淋巴瘤专业委员会, 中国医师协会肿瘤医师分会, 中国医疗保健国际交流促进会肿瘤内科分会. 中国淋巴瘤治疗指南(2021年版) [J]. 中华肿瘤杂志, 2021, 43(7): 707-735. [Google Scholar] [CrossRef] [PubMed]
[2] Goldfinger, M. and Cooper, D.L. (2021) Lenalido-mide in DLBCL: Are We Past the Cell of Origin? Clinical Advances in Hematology & Oncology, 19, 320-325.
[3] 肖远喆, 张清媛. 弥漫性大B细胞淋巴瘤免疫治疗进展[J]. 现代肿瘤学, 2022, 30(18): 3441-3444.
[4] Arneth, B. (2019) Tumor Microenvironment. Medicina, 56, Article 15. [Google Scholar] [CrossRef] [PubMed]
[5] Spill, F., Reynolds, D.S., Kamm, R.D. and Zaman, M.H. (2016) Impact of the Physical Microenvironment on Tumor Progres-sion and Metastasis. Current Opinion in Biotechnology, 40, 41-48. [Google Scholar] [CrossRef] [PubMed]
[6] Del Prete, A., Schioppa, T., Tiberio, L., et al. (2017) Leukocyte Trafficking in Tumor Microenvironment. Current Opinion in Pharmacology, 35, 40-47. [Google Scholar] [CrossRef] [PubMed]
[7] Dunn, G.P., Old, L.J. and Schreiber, R.D. (2004) The Three Es of Cancer Immunoediting. Annual Review of Immunology, 22, 329-360. [Google Scholar] [CrossRef] [PubMed]
[8] Cycon, K.A., Rimsza, L.M. and Murphy, S.P. (2009) Alterations in CIITA Constitute a Common Mechanism Accounting for Downregulation of MHC Class II Ex-pression in Diffuse Large B-Cell Lymphoma (DLBCL). Experimental Hematology, 37, 184-194. [Google Scholar] [CrossRef] [PubMed]
[9] Wada, N., Zaki, M.A., Hori, Y., Hashimoto, K., Tsukaguchi, M., Tatsumi, Y., Ishikawa, J., Tominaga, N., Sakoda, H., Take, H., Tsudo, M., Kuwayama, M., Morii, E., Aozasa, K. and Osaka Lymphoma Study Group (2012) Tumour-Associated Macrophages in Diffuse Large B-Cell Lymphoma: A Study of the Osaka Lymphoma Study Group. Histopathology, 60, 313-319. [Google Scholar] [CrossRef] [PubMed]
[10] Lau, S.K., Chu, P.G. and Weiss, L.M. (2004) CD163: A Specific Marker of Macrophages in Paraffin-Embedded Tissue Samples. American Journal of Clinical Pathology, 122, 794-801. [Google Scholar] [CrossRef
[11] Riihijärvi, S., Fiskvik, I., Taskinen, M., Vaja-vaara, H., Tikkala, M., Yri, O., Karjalainen-Lindsberg, M.L., Delabie, J., Smeland, E., Holte, H. and Leppä, S. (2015) Prognostic Influence of Macrophages in Patients with Diffuse Large B-Cell Lymphoma: A Correlative Study from a Nordic Phase II Trial. Haematologica, 100, 238-245. [Google Scholar] [CrossRef] [PubMed]
[12] Nam, S.J., Go, H., Paik, J.H., Kim, T.M., Heo, D.S., Kim, C.W. and Jeon, Y.K. (2014) An Increase of M2 Macrophages Predicts Poor Prognosis in Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone. Leukemia & Lymphoma, 55, 2466-2476. [Google Scholar] [CrossRef] [PubMed]
[13] 罗燕珍, 周达, 陈思静, 廖成成, 王明月, 谭晓虹, 柯晴, 岑洪. 肿瘤相关巨噬细胞与弥漫大B细胞淋巴瘤预后的关系[J]. 中国癌症防治杂志, 2022, 14(1): 87-93.
[14] Ruffell, B., Affara, N.I. and Coussens, L.M. (2012) Differential Macrophage Programming in the Tumor Microenvironment. Trends in Immunology, 33, 119-126. [Google Scholar] [CrossRef] [PubMed]
[15] Matsuki, E., Bohn, O.L., El Jamal, S., Pichardo, J.D., Zelenetz, A.D., Younes, A. and Teruya-Feldstein, J. (2019) Lympho-cyte-to-Monocyte Ratio May Serve as a Better Prognostic Indicator than Tumor-associated Macrophages in DLBCL Treated with Rituximab. Applied Immunohistochemistry & Molecular Morphology, 27, 572-580. [Google Scholar] [CrossRef
[16] Ménétrier-Caux, C., Ray-Coquard, I., Blay, J.Y. and Caux, C. (2019) Lymphopenia in Cancer Patients and Its Effects on Response to Immunotherapy: An Opportunity for Combi-nation with Cytokines? Journal for ImmunoTherapy of Cancer, 7, 85. [Google Scholar] [CrossRef] [PubMed]
[17] 傅郗雨菁, 杨顺娥. 中性粒细胞与淋巴细胞比值对弥漫性大B细胞淋巴瘤预后判断的意义[J]. 现代肿瘤医学, 2022, 30(22): 4162-4166.
[18] Mu, S.D., Ai, L.S., Fan, F.J., Qin, Y., Sun, C.Y. and Hu, Y. (2018) Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Diffuse Large B Cell Lympho-ma Patients: An Updated Dose-Response Meta-Analysis. Cancer Cell International, 18, Article No. 119. [Google Scholar] [CrossRef] [PubMed]
[19] Wang, J., Zhou, X., Liu, Y., Li, Z. and Li, X. (2017) Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Diffuse Large B-Cell Lymphoma: A Meta-Analysis. PLOS ONE, 12, e0176008. [Google Scholar] [CrossRef] [PubMed]
[20] Feng, J.H., Wang, Z.J., Guo, X.P., Chen, Y.Y., Cheng, Y.P. and Tang, Y.M. (2012) Prognostic Significance of Absolute Lymphocyte Count at Diagnosis of Diffuse Large B-Cell Lymphoma: A Meta-Analysis. International Journal of Hematology, 95, 143-148. [Google Scholar] [CrossRef] [PubMed]
[21] Annibali, O., Hohaus, S., Marchesi, F., Cantonetti, M., Di Rocco, A., Tomarchio, V., Di Napoli, A., Pelliccia, S., Battistini, R., Anticoli Borza, P., Abruzzese, E., Cenfra, N., Andriani, A., Tesei, C., Alma, E., Palombi, F., Pupo, L., Petrucci, L., Becilli, M., Maiolo, E., Bellesi, S., Cuccaro, A., D’Alò, F. and Cox Maria, C. (2019) The Neutrophil/Lymphocyte Ratio ≥ 3.5 Is a Prognostic Marker in Diffuse Large B-Cell Lym-phoma: A Retrospective Analysis from the Database of the Italian Regional Network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI). Leukemia & Lymphoma, 60, 3386-3394. [Google Scholar] [CrossRef] [PubMed]
[22] Antonangeli, F., Natalini, A., Garassino, M.C., et al. (2020) Regulation of PD-L1 Expression by NF-κB in Cancer. Frontiers in Immunology, 11, Article 584626. [Google Scholar] [CrossRef] [PubMed]
[23] Lesokhin, A.M., Ansell, S.M., Armand, P., Scott, E.C., Halwani, A., Gutierrez, M., et al. (2016) Nivolumab in Patients with Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. Journal of Clinical Oncology, 34, 2698-2704. [Google Scholar] [CrossRef
[24] Hernandez-Ilizaliturri, F.J., Deeb, G., Zinzani, P.L., Pileri, S.A., Malik, F., Macon, W.R., et al. (2011) Higher Response to Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Nongerminal Center B-Cell-Like than in Germinal Center B-Cell-Like Phenotype. Cancer, 117, 5058-5066. [Google Scholar] [CrossRef] [PubMed]
[25] Feldman, T., Mato, A.R., Chow, K.F., Protomastro, E.A., Yannotti, K.M., Bhattacharyya, P., et al. (2014) Addition of Lenalidomide to Rituximab, Ifosfamide, Carboplatin, Etoposide (RICER) in First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma. British Journal of Haematology, 166, 77-83. [Google Scholar] [CrossRef] [PubMed]
[26] Martin, A., Redondo, A.M., Dlouhy, I., Salar, A., Gonzalez-Barca, E., Canales, M., et al. (2016) Lenalidomide in Combination with R‑ESHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 1b Study from GELTAMO Group. British Journal of Haematology, 173, 245-252. [Google Scholar] [CrossRef] [PubMed]
[27] Ghesquieres, H., Chevrier, M., Laadhari, M., Chinot, O., Choquet, S., Molucon-Chabrot, C., et al. (2019) Lenalidomide in Combination with Intravenous Rituximab (REVRI) in Re-lapsed/Refractory Primary CNS Lymphoma or Primary Intraocular Lymphoma: A Multicenter Prospective “Proof of Concept” Phase II Study of the French Oculo‑Cerebral Lymphoma (LOC) Network and the Lymphoma Study Associa-tion (LYSA) Dagger. Annals of Oncology, 30, 621-628. [Google Scholar] [CrossRef] [PubMed]
[28] Rubenstein, J.L., Geng, H., Fraser, E.J., Formaker, P., Chen, L., Sharma, J., et al. (2018) Phase 1 Investigation of Lenalido-mide/Rituximab plus Outcomes of Lenalidomide Maintenance in Relapsed CNS Lymphoma. Blood Advances, 2, 1595-1607. [Google Scholar] [CrossRef] [PubMed]
[29] Niiro, H. and Clark, E.A. (2002) Regulation of B-Cell Fate by Antigen-Receptor Signals. Nature Reviews Immunology, 2, 945-956. [Google Scholar] [CrossRef] [PubMed]
[30] Merolle, M.I., Ahmed, M., Nomie, K., et al. (2018) The B Cell Receptor Sig-naling Pathway in Mantle Cell Lymphoma. Oncotarget, 9, 25332-25341. [Google Scholar] [CrossRef] [PubMed]
[31] Shadman, M., Pasquini, M., Ahn, K.W., Chen, Y., Turtle, C.J., Hematti, P., Cohen, J.B., Khimani, F., Ganguly, S., Merryman, R.W., Yared, J.A., Locke, F.L., Ahmed, N., Munshi, P.N., Beitinjaneh, A., Reagan, P.M., Herrera, A.F., Sauter, C.S., Kharfan-Dabaja, M.A. and Hamadani, M. (2022) Au-tologous Transplant vs Chimeric Antigen Receptor T-Cell Therapy for Relapsed DLBCL in Partial Remission. Blood, 139, 1330-1339. [Google Scholar] [CrossRef] [PubMed]
[32] 黄玉洁, 黄鑫, 郭宝平, 等. 基于肿瘤免疫微环境的弥漫大B细胞淋巴瘤预后分析[J]. 肿瘤预防与治疗, 2021, 34(2): 108-116.
[33] Villanueva, M.T. (2020) Macrophages Get a CAR. Nature Reviews Cancer, 20, 300. [Google Scholar] [CrossRef] [PubMed]
[34] Pan, K., Farrukh, H., Chittepu, V.C.S.R., et al. (2022) CAR Race to Cancer Immunotherapy: From CAR-T, CAR NK to CAR Macrophage Therapy. Journal of Experimental and Clinical Cancer Research, 41, Article No. 119. [Google Scholar] [CrossRef] [PubMed]
[35] Schmitt, A., Xu, W., Bucher, P., Grimm, M., Konantz, M., Horn, H., Zapukhlyak, M., Berning, P., Brändle, M., Jarboui, M.A., Schönfeld, C., Boldt, K., Rosenwald, A., Ott, G., Grau, M., Klener, P., Vockova, P., Lengerke, C., Lenz, G., Schulze-Osthoff, K. and Hailfinger, S. (2021) Dimethyl Fumarate Induces Ferroptosis and Impairs NF-κB/STAT3 Signaling in DLBCL. Blood, 138, 871-884. [Google Scholar] [CrossRef] [PubMed]